BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. DFTX
10. NKE

Go back to BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

BioMarin Pharma (BMRN) Posts FDA Committee Meeting Presentation on Drisapersen

November 24, 2015 10:05 AM EST

BioMarin Pharma (NASDAQ: BMRN) announced that the Companys presentation from the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA)s meeting for Kyndrisa (drisapersen) is now available. The Advisory Committee is meeting today to... More